The dual roles of immunity in ALS: Injury overrides protection

Neurobiology of Disease

Volumn 77, Issue , 2015, Pages 1-12

  Murdock, Benjamin J ^a   Bender, Diane E ^a   Segal, Benjamin M ^a   Feldman, Eva L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Amyotrophic lateral sclerosis; Central nervous system; Debris clearance; Immune response; Monocytes; Mutant SOD1; Repair; Toll like receptors

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA;

ADAPTIVE IMMUNITY; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; AUTOPHAGY; BLOOD BRAIN BARRIER; BLOOD SPINAL CORD BARRIER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; IMMUNITY; INNATE IMMUNITY; MICROGLIA; MONOCYTE; MOTONEURON; NECROPTOSIS; NERVE DEGENERATION; NERVE REGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PERMEABILITY BARRIER; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; REGULATORY T LYMPHOCYTE; REVIEW; UNFOLDED PROTEIN RESPONSE; IMMUNOLOGY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

AMYOTROPHIC LATERAL SCLEROSIS; HUMANS; IMMUNITY; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84924105359     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.02.017     Document Type: Review

References (197)

1. Aebischer J., et al. Elevated levels of IFNgamma and LIGHT in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. Eur. J. Neurol. 2012, 19(752-9):e45-e46.
2. Alexianu M.E., et al. Apoptotic cell death of a hybrid motoneuron cell line induced by immunoglobulins from patients with amyotrophic lateral sclerosis. J. Neurochem. 1994, 63:2365-2368.
3. Alexianu M.E., et al. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 2001, 57:1282-1289.
4. Arnold E.S., et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E736-E745.
5. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
6. Banerjee R., et al. Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS One 2008, 3:e2740.
7. Barber S.C., Shaw P.J. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic. Biol. Med. 2010, 48:629-641.
8. Barrette B., et al. Requirement of myeloid cells for axon regeneration. J. Neurosci. 2008, 28:9363-9376.
9. Beers D.R., et al. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:16021-16026.
10. Beers D.R., et al. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:15558-15563.
11. Beers D.R., et al. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain 2011, 134:1293-1314.
12. Beers D.R., et al. Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. Brain Behav. Immun. 2011, 25:1025-1035.
13. Blokhuis A.M., et al. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol. 2013, 125:777-794.
14. Boivin A., et al. Toll-like receptor signaling is critical for Wallerian degeneration and functional recovery after peripheral nerve injury. J. Neurosci. 2007, 27:12565-12576.
15. Bonaldi T., et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 2003, 22:5551-5560.
16. Bosco D.A., et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat. Neurosci. 2010, 13:1396-1403.
17. Bruijn L.I., et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998, 281:1851-1854.
18. Bsibsi M., et al. Broad expression of Toll-like receptors in the human central nervous system. J. Neuropathol. Exp. Neurol. 2002, 61:1013-1021.
19. Butovsky O., et al. Selective ablation of bone marrow-derived dendritic cells increases amyloid plaques in a mouse Alzheimer's disease model. Eur. J. Neurosci. 2007, 26:413-416.
20. Butovsky O., et al. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J. Clin. Invest. 2012, 122:3063-3087.
21. Butterfield T.A., et al. The dual roles of neutrophils and macrophages in inflammation: a critical balance between tissue damage and repair. J. Athl. Train. 2006, 41:457-465.
22. Casula M., et al. Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience 2011, 179:233-243.
23. Chang Y., et al. Messenger RNA oxidation occurs early in disease pathogenesis and promotes motor neuron degeneration in ALS. PLoS One 2008, 3:e2849.
24. Chen H., et al. Head injury and amyotrophic lateral sclerosis. Am. J. Epidemiol. 2007, 166:810-816.
25. Chio A., et al. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain 2005, 128:472-476.
26. Chio A., et al. ALS in Italian professional soccer players: the risk is still present and could be soccer-specific. Amyotroph. Lateral Scler. 2009, 10:205-209.
27. Chiu I.M., et al. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:17913-17918.
28. Christou Y.A., et al. Wild-type but not mutant SOD1 transgenic astrocytes promote the efficient generation of motor neuron progenitors from mouse embryonic stem cells. BMC Neurosci. 2013, 14:126.
29. Coban A., et al. Serum anti-neuronal antibodies in amyotrophic lateral sclerosis. Int. J. Neurosci. 2013, 123:557-562.
30. Cone R.E., et al. The induction of circulating, ACAID-inducing monocytes requires CCR2/CCL2-dependent migration of circulating F4/80(+) cells into the anterior chamber. Ophthalmol. Eye Dis. 2010, 2:57-68.
31. Cudkowicz M.E., et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann. Neurol. 2006, 60:22-31.
32. DeJesus-Hernandez M., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011, 72:245-256.
33. Deshpande P., et al. Cutting edge: CNS CD11c+ cells from mice with encephalomyelitis polarize Th17 cells and support CD25+ CD4+ T cell-mediated immunosuppression, suggesting dual roles in the disease process. J. Immunol. 2007, 178:6695-6699.
34. Ding H.S., et al. The HMGB1-TLR4 axis contributes to myocardial ischemia/reperfusion injury via regulation of cardiomyocyte apoptosis. Gene 2013, 527:389-393.
35. Elliott M.R., Ravichandran K.S. Clearance of apoptotic cells: implications in health and disease. J. Cell Biol. 2010, 189:1059-1070.
36. Engelhardt J.I., et al. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch. Neurol. 1993, 50:30-36.
37. Evans T.A., et al. High-resolution intravital imaging reveals that blood-derived macrophages but not resident microglia facilitate secondary axonal dieback in traumatic spinal cord injury. Exp. Neurol. 2014, 254:109-120.
38. Fecto F., et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch. Neurol. 2011, 68:1440-1446.
39. Ferlazzo G., et al. Dendritic cells generated either from CD34+ progenitor cells or from monocytes differ in their ability to activate antigen-specific CD8+ T cells. J. Immunol. 1999, 163:3597-3604.
40. Fernandez-Ruiz V., et al. Effect of nitric oxide in the differentiation of human monocytes to dendritic cells. Immunol. Lett. 2004, 93:87-95.
41. Fernandez-Ruiz V., et al. Production of nitric oxide and self-nitration of proteins during monocyte differentiation to dendritic cells. J. Physiol. Biochem. 2005, 61:517-525.
42. Fiala M., et al. IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients. J. Neuroinflammation 2010, 7:76.
43. Gao T.L., et al. Expression of HMGB1 and RAGE in rat and human brains after traumatic brain injury. J. Trauma Acute Care Surg. 2012, 72:643-649.
44. Garbuzova-Davis S., et al. Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS. PLoS One 2007, 2:e1205.
45. Ge Z., et al. Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis. Exp. Neurol. 2013, 241:56-66.
46. Gitcho M.A., et al. TDP-43 A315T mutation in familial motor neuron disease. Ann. Neurol. 2008, 63:535-538.
47. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 2003, 3:23-35.
48. Gordon P.H., et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007, 6:1045-1053.
49. Gros-Louis F., et al. A frameshift deletion in peripherin gene associated with amyotrophic lateral sclerosis. J. Biol. Chem. 2004, 279:45951-45956.
50. Gruzman A., et al. Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12524-12529.
51. Gsponer J., Vendruscolo M. Theoretical approaches to protein aggregation. Protein Pept. Lett. 2006, 13:287-293.
52. Gurney M.E., et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994, 264:1772-1775.
53. Hammad H., et al. Inflammatory dendritic cells-not basophils-are necessary and sufficient for induction of Th2 immunity to inhaled house dust mite allergen. J. Exp. Med. 2010, 207:2097-2111.
54. Havenith C.E., et al. Separation of alveolar macrophages and dendritic cells via autofluorescence: phenotypical and functional characterization. J. Leukoc. Biol. 1993, 53:504-510.
55. Henkel J.S., et al. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann. Neurol. 2004, 55:221-235.
56. Henkel J.S., et al. The chemokine MCP-1 and the dendritic and myeloid cells it attracts are increased in the mSOD1 mouse model of ALS. Mol. Cell. Neurosci. 2006, 31:427-437.
57. Henkel J.S., et al. Decreased mRNA expression of tight junction proteins in lumbar spinal cords of patients with ALS. Neurology 2009, 72:1614-1616.
58. Henkel J.S., et al. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol. Med. 2013, 5:64-79.
59. Henn A., et al. TLR2 hypersensitivity of astrocytes as functional consequence of previous inflammatory episodes. J. Immunol. 2011, 186:3237-3247.
60. Herbst B., et al. CD34+ peripheral blood progenitor cell and monocyte derived dendritic cells: a comparative analysis. Br. J. Haematol. 1997, 99:490-499.
61. Hernandez S., et al. Neurotoxic species of misfolded SOD1G93A recognized by antibodies against the P2X4 subunit of the ATP receptor accumulate in damaged neurons of transgenic animal models of amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2010, 69:176-187.
62. Huang G., et al. Death receptor 6 (DR6) antagonist antibody is neuroprotective in the mouse SOD1G93A model of amyotrophic lateral sclerosis. Cell Death Dis. 2013, 4:e841.
63. Ifergan I., et al. The blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. Brain 2008, 131:785-799.
64. Iida A., et al. A functional variant in ZNF512B is associated with susceptibility to amyotrophic lateral sclerosis in Japanese. Hum. Mol. Genet. 2011, 20:3684-3692.
65. Jaiswal M., et al. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 2000, 60:184-190.
66. Jaiswal M., et al. Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. Gastroenterology 2001, 120:190-199.
67. Johnson J.O., et al. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat. Neurosci. 2014, 17:664-666.
68. Joubert M.K., et al. Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J. Biol. Chem. 2012, 287:25266-25279.
69. Kaczmarek A., et al. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity 2013, 38:209-223.
70. Kandasamy M., et al. TGF-beta signalling in the adult neurogenic niche promotes stem cell quiescence as well as generation of new neurons. J. Cell. Mol. Med. 2014, 18(7):1444-1459.
71. Kang J., Rivest S. MyD88-deficient bone marrow cells accelerate onset and reduce survival in a mouse model of amyotrophic lateral sclerosis. J. Cell Biol. 2007, 179:1219-1230.
72. Kang S.H., et al. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat. Neurosci. 2013, 16:571-579.
73. Kano O., et al. Peripheral nerve inflammation in ALS mice: cause or consequence. Neurology 2012, 78:833-835.
74. Kawaguchi-Niida M., et al. MCP-1/CCR2 signaling-mediated astrocytosis is accelerated in a transgenic mouse model of SOD1-mutated familial ALS. Acta Neuropathol. Commun. 2013, 1:21.
75. Kawamata T., et al. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol. 1992, 140:691-707.
76. Kettenmann H., et al. Microglia: new roles for the synaptic stripper. Neuron 2013, 77:10-18.
77. Kierdorf K., et al. Bone marrow cell recruitment to the brain in the absence of irradiation or parabiosis bias. PLoS One 2013, 8:e58544.
78. Kim C.F., Moalem-Taylor G. Detailed characterization of neuro-immune responses following neuropathic injury in mice. Brain Res. 2011, 1405:95-108.
79. Kim S., et al. Signaling of high mobility group box 1 (HMGB1) through toll-like receptor 4 in macrophages requires CD14. Mol. Med. 2013, 19:88-98.
80. Kraaij M.D., et al. Induction of regulatory T cells by macrophages is dependent on production of reactive oxygen species. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:17686-17691.
81. Kuhn T.B. Oxygen radicals elicit paralysis and collapse of spinal cord neuron growth cones upon exposure to proinflammatory cytokines. Biomed. Res. Int. 2014, 2014:191767.
82. Kuhnlein P., et al. Two German kindreds with familial amyotrophic lateral sclerosis due to TARDBP mutations. Arch. Neurol. 2008, 65:1185-1189.
83. Kurimoto T., et al. Neutrophils express oncomodulin and promote optic nerve regeneration. J. Neurosci. 2013, 33:14816-14824.
84. Kwiatkowski T.J., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009, 323:1205-1208.
85. Laouar Y., et al. TGF-beta signaling in dendritic cells is a prerequisite for the control of autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10865-10870.
86. Lehman E.J., et al. Neurodegenerative causes of death among retired National Football League players. Neurology 2012, 79:1970-1974.
87. Li H., et al. CD11c+CD11b+ dendritic cells play an important role in intravenous tolerance and the suppression of experimental autoimmune encephalomyelitis. J. Immunol. 2008, 181:2483-2493.
88. Liao B., et al. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp. Neurol. 2012, 237:147-152.
89. Lino M.M., et al. Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J. Neurosci. 2002, 22:4825-4832.
90. Liu J., et al. Elevation of the Hsp70 chaperone does not effect toxicity in mouse models of familial amyotrophic lateral sclerosis. J. Neurochem. 2005, 93:875-882.
91. Lo Coco D., et al. Distribution and cellular localization of high mobility group box protein 1 (HMGB1) in the spinal cord of a transgenic mouse model of ALS. Neurosci. Lett. 2007, 412:73-77.
92. London A., et al. Neuroprotection and progenitor cell renewal in the injured adult murine retina requires healing monocyte-derived macrophages. J. Exp. Med. 2011, 208:23-39.
93. London A., et al. Microglia and monocyte-derived macrophages: functionally distinct populations that act in concert in CNS plasticity and repair. Front. Cell. Neurosci. 2013, 7:34.
94. Lunn J.S., et al. Concise review: stem cell therapies for amyotrophic lateral sclerosis: recent advances and prospects for the future. Stem Cells 2014, 32:1099-1109.
95. Ma D., et al. The neurotoxic effect of astrocytes activated with toll-like receptor ligands. J. Neuroimmunol. 2013, 254:10-18.
96. Mantovani S., et al. Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process. J. Neuroimmunol. 2009, 210:73-79.
97. Maruyama H., et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010, 465:223-226.
98. May C., et al. Highly immunoreactive IgG antibodies directed against a set of twenty human proteins in the sera of patients with amyotrophic lateral sclerosis identified by protein array. PLoS One 2014, 9:e89596.
99. Mehta P., et al. Prevalence of amyotrophic lateral sclerosis - United States, 2010-2011. MMWR Surveill. Summ. 2014, 63(Suppl. 7):1-14.
100. Meininger V., et al. Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial. Neurology 2006, 66:88-92.
101. Meininger V., et al. Glatiramer acetate has no impact on disease progression in ALS at 40mg/day: a double-blind, randomized, multicentre, placebo-controlled trial. Amyotroph. Lateral Scler. 2009, 10:378-383.
102. Mitchell J.D., Borasio G.D. Amyotrophic lateral sclerosis. Lancet 2007, 369:2031-2041.
103. Mitrecic D., et al. Distribution, differentiation, and survival of intravenously administered neural stem cells in a rat model of amyotrophic lateral sclerosis. Cell Transplant. 2010, 19:537-548.
104. Miyazaki K., et al. Spinal anterior horn has the capacity to self-regenerate in amyotrophic lateral sclerosis model mice. J. Neurosci. Res. 2009, 87:3639-3648.
105. Miyazaki K., et al. Disruption of neurovascular unit prior to motor neuron degeneration in amyotrophic lateral sclerosis. J. Neurosci. Res. 2011, 89:718-728.
106. Mohammad M.G., et al. Immune cell trafficking from the brain maintains CNS immune tolerance. J. Clin. Invest. 2014, 124:1228-1241.
107. Morimoto N., et al. Increased autophagy in transgenic mice with a G93A mutant SOD1 gene. Brain Res. 2007, 1167:112-117.
108. Murdock B.J., et al. Coevolution of TH1, TH2, and TH17 responses during repeated pulmonary exposure to Aspergillus fumigatus conidia. Infect. Immun. 2011, 79:125-135.
109. Nagano I., et al. Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a mouse model of amyotrophic lateral sclerosis. J. Neurol. Sci. 2005, 235:61-68.
110. Nagano I., et al. Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis. Neurol. Res. 2005, 27:768-772.
111. Nagata T., et al. Elevation of MCP-1 and MCP-1/VEGF ratio in cerebrospinal fluid of amyotrophic lateral sclerosis patients. Neurol. Res. 2007, 29:772-776.
112. Naor S., et al. Development of ALS-like disease in SOD-1 mice deficient of B lymphocytes. J. Neurol. 2009, 256:1228-1235.
113. Napoli I., Neumann H. Microglial clearance function in health and disease. Neuroscience 2009, 158:1030-1038.
114. Naumenko N., et al. Gender-specific mechanism of synaptic impairment and its prevention by GCSF in a mouse model of ALS. Front. Cell. Neurosci. 2011, 5:26.
115. Neumann M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314:130-133.
116. Neumann H., et al. Debris clearance by microglia: an essential link between degeneration and regeneration. Brain 2009, 132:288-295.
117. Nicaise C., et al. Impaired blood-brain and blood-spinal cord barriers in mutant SOD1-linked ALS rat. Brain Res. 2009, 1301:152-162.
118. Nicaise C., et al. Brain and spinal cord affected by amyotrophic lateral sclerosis induce differential growth factors expression in rat mesenchymal and neural stem cells. Neuropathol. Appl. Neurobiol. 2011, 37:179-188.
119. Niedbala W., et al. Nitric oxide preferentially induces type 1T cell differentiation by selectively up-regulating IL-12 receptor beta 2 expression via cGMP. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:16186-16191.
120. Niedbala W., et al. Nitric oxide induces CD4+CD25+ Foxp3 regulatory T cells from CD4+CD25 T cells via p53, IL-2, and OX40. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:15478-15483.
121. Niedbala W., et al. Nitric oxide-induced regulatory T cells inhibit Th17 but not Th1 cell differentiation and function. J. Immunol. 2013, 191:164-170.
122. Noda M., et al. FGF-2 released from degenerating neurons exerts microglial-induced neuroprotection via FGFR3-ERK signaling pathway. J. Neuroinflammation 2014, 11:76.
123. Ohta Y., et al. Therapeutic benefits of intrathecal protein therapy in a mouse model of amyotrophic lateral sclerosis. J. Neurosci. Res. 2008, 86:3028-3037.
124. Pagani M.R., et al. Autoimmunity in amyotrophic lateral sclerosis: past and present. Neurol. Res. Int. 2011, 2011:497080.
125. Paolucci C., et al. Synergism of nitric oxide and maturation signals on human dendritic cells occurs through a cyclic GMP-dependent pathway. J. Leukoc. Biol. 2003, 73:253-262.
126. Parajuli B., et al. GM-CSF increases LPS-induced production of proinflammatory mediators via upregulation of TLR4 and CD14 in murine microglia. J. Neuroinflammation 2012, 9:268.
127. Parone P.A., et al. Enhancing mitochondrial calcium buffering capacity reduces aggregation of misfolded SOD1 and motor neuron cell death without extending survival in mouse models of inherited amyotrophic lateral sclerosis. J. Neurosci. 2013, 33:4657-4671.
128. Patel P., et al. Adeno-associated virus-mediated delivery of a recombinant single-chain antibody against misfolded superoxide dismutase for treatment of amyotrophic lateral sclerosis. Mol. Ther. 2014, 22:498-510.
129. Peng Y., et al. Innate and adaptive immune response to apoptotic cells. J. Autoimmun. 2007, 29:303-309.
130. Perruche S., et al. CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat. Med. 2008, 14:528-535.
131. Pickles S., et al. Mitochondrial damage revealed by immunoselection for ALS-linked misfolded SOD1. Hum. Mol. Genet. 2013, 22:3947-3959.
132. Pineau I., et al. Astrocytes initiate inflammation in the injured mouse spinal cord by promoting the entry of neutrophils and inflammatory monocytes in an IL-1 receptor/MyD88-dependent fashion. Brain Behav. Immun. 2010, 24:540-553.
133. Pollari E., et al. The role of oxidative stress in degeneration of the neuromuscular junction in amyotrophic lateral sclerosis. Front. Cell. Neurosci. 2014, 8:131.
134. Pope H.M., Voigt M.M. Peripheral glia have a pivotal role in the initial response to axon degeneration of peripheral sensory neurons in zebrafish. PLoS One 2014, 9:e103283.
135. Pramatarova A., et al. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J. Neurosci. 2001, 21:3369-3374.
136. Rajbhandari L., et al. Toll-like receptor 4 deficiency impairs microglial phagocytosis of degenerating axons. Glia 2014, 62(12):1982-1991.
137. Rakhit R., et al. An immunological epitope selective for pathological monomer-misfolded SOD1 in ALS. Nat. Med. 2007, 13:754-759.
138. Raoul C., et al. Motoneuron death triggered by a specific pathway downstream of Fas. potentiation by ALS-linked SOD1 mutations. Neuron 2002, 35:1067-1083.
139. Re D.B., et al. Necroptosis drives motor neuron death in models of both sporadic and familial ALS. Neuron 2014, 81:1001-1008.
140. Renton A.E., et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011, 72:257-268.
141. Rentzos M., et al. Interleukin-17 and interleukin-23 are elevated in serum and cerebrospinal fluid of patients with ALS: a reflection of Th17 cells activation?. Acta Neurol. Scand. 2010, 122:425-429.
142. Rentzos M., et al. Alterations of T cell subsets in ALS: a systemic immune activation?. Acta Neurol. Scand. 2012, 125:260-264.
143. Rentzos M., et al. Humoral immune activation in amyotrophic lateral sclerosis patients. Neurol. Int. 2013, 5:e3.
144. Rodrigues M.C., et al. Neurovascular aspects of amyotrophic lateral sclerosis. Int. Rev. Neurobiol. 2012, 102:91-106.
145. Rolls A., et al. Toll-like receptors modulate adult hippocampal neurogenesis. Nat. Cell Biol. 2007, 9:1081-1088.
146. Rotunno M.S., Bosco D.A. An emerging role for misfolded wild-type SOD1 in sporadic ALS pathogenesis. Front. Cell. Neurosci. 2013, 7:253.
147. Rovere-Querini P., et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 2004, 5:825-830.
148. Rutault K., et al. Reactive oxygen species activate human peripheral blood dendritic cells. Free Radic. Biol. Med. 1999, 26:232-238.
149. Sagar D., et al. Dendritic cell CNS recruitment correlates with disease severity in EAE via CCL2 chemotaxis at the blood-brain barrier through paracellular transmigration and ERK activation. J. Neuroinflammation 2012, 9:245.
150. Sanjuan M.A., et al. Toll-like receptor signalling in macrophages links the autophagy pathway to phagocytosis. Nature 2007, 450:1253-1257.
151. Saresella M., et al. T helper-17 activation dominates the immunologic milieu of both amyotrophic lateral sclerosis and progressive multiple sclerosis. Clin. Immunol. 2013, 148:79-88.
152. Sargsyan S.A., et al. Mutant SOD1 G93A microglia have an inflammatory phenotype and elevated production of MCP-1. Neuroreport 2009, 20:1450-1455.
153. Scaffidi P., et al. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195.
154. Schwartz M., et al. Boosting T-cell immunity as a therapeutic approach for neurodegenerative conditions: the role of innate immunity. Neuroscience 2009, 158:1133-1142.
155. Shami P.J., Weinberg J.B. Differential effects of nitric oxide on erythroid and myeloid colony growth from CD34+ human bone marrow cells. Blood 1996, 87:977-982.
156. Shechter R., et al. Toll-like receptor 4 restricts retinal progenitor cell proliferation. J. Cell Biol. 2008, 183:393-400.
157. Shechter R., et al. Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. PLoS Med. 2009, 6:e1000113.
158. Simard A.R., Rivest S. Neuroprotective effects of resident microglia following acute brain injury. J. Comp. Neurol. 2007, 504:716-729.
159. Simard A.R., et al. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 2006, 49:489-502.
160. Sioud M., Floisand Y. TLR agonists induce the differentiation of human bone marrow CD34+ progenitors into CD11c+CD80/86+ DC capable of inducing a Th1-type response. Eur. J. Immunol. 2007, 37:2834-2846.
161. Smith R.G., et al. Cytotoxicity of immunoglobulins from amyotrophic lateral sclerosis patients on a hybrid motoneuron cell line. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:3393-3397.
162. Steinacker P., et al. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch. Neurol. 2008, 65:1481-1487.
163. Swarup V., et al. Abnormal regenerative responses and impaired axonal outgrowth after nerve crush in TDP-43 transgenic mouse models of amyotrophic lateral sclerosis. J. Neurosci. 2012, 32:18186-18195.
164. Takazawa T., et al. Familial amyotrophic lateral sclerosis with a novel G85S mutation of superoxide dismutase 1 gene: clinical features of lower motor neuron disease. Intern. Med. 2010, 49:183-186.
165. Tanaka K., et al. A dopamine receptor antagonist L-745,870 suppresses microglia activation in spinal cord and mitigates the progression in ALS model mice. Exp. Neurol. 2008, 211:378-386.
166. Tanaka K., et al. Bromocriptine methylate suppresses glial inflammation and moderates disease progression in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 2011, 232:41-52.
167. Tanaka K., et al. A novel acylaminoimidazole derivative, WN1316, alleviates disease progression via suppression of glial inflammation in ALS mouse model. PLoS One 2014, 9:e87728.
168. Taylor E.L., et al. Nitric oxide: a key regulator of myeloid inflammatory cell apoptosis. Cell Death Differ. 2003, 10:418-430.
169. Tegenge M.A., et al. Curcumin protects axons from degeneration in the setting of local neuroinflammation. Exp. Neurol. 2014, 253:102-110.
170. Tian F., et al. In vivo optical imaging of motor neuron autophagy in a mouse model of amyotrophic lateral sclerosis. Autophagy 2011, 7:985-992.
171. Ticozzi N., et al. Paraoxonase gene mutations in amyotrophic lateral sclerosis. Ann. Neurol. 2010, 68:102-107.
172. Turner M.R., et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol. Dis. 2004, 15:601-609.
173. Turner M.R., et al. Autoimmune disease preceding amyotrophic lateral sclerosis: an epidemiologic study. Neurology 2013, 81:1222-1225.
174. Urushitani M., et al. Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat. Neurosci. 2006, 9:108-118.
175. Urushitani M., et al. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:2495-2500.
176. van Noort J.M., Bsibsi M. Toll-like receptors in the CNS: implications for neurodegeneration and repair. Prog. Brain Res. 2009, 175:139-148.
177. Vande Velde C., et al. Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:4022-4027.
178. Wang L., et al. Restricted expression of mutant SOD1 in spinal motor neurons and interneurons induces motor neuron pathology. Neurobiol. Dis. 2008, 29:400-408.
179. Wang L., et al. The unfolded protein response in familial amyotrophic lateral sclerosis. Hum. Mol. Genet. 2011, 20:1008-1015.
180. Warita H., et al. Early decrease of survival signal-related proteins in spinal motor neurons of presymptomatic transgenic mice with a mutant SOD1 gene. Apoptosis 2001, 6:345-352.
181. Williamson T.L., Cleveland D.W. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat. Neurosci. 1999, 2:50-56.
182. Winer L., et al. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol. 2013, 70:201-207.
183. Winkler E.A., et al. Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol. 2013, 125:111-120.
184. Winkler E.A., et al. Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:E1035-E1042.
185. Wu C.H., et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature 2012, 488:499-503.
186. Xiao Q., et al. Mutant SOD1(G93A) microglia are more neurotoxic relative to wild-type microglia. J. Neurochem. 2007, 102:2008-2019.
187. Xie Y., et al. Inflammatory mediators and growth factors in the spinal cord of G93A SOD1 rats. Neuroreport 2004, 15:2513-2516.
188. Yang J., et al. T cell-derived inducible nitric oxide synthase switches off Th17 cell differentiation. J. Exp. Med. 2013, 210:1447-1462.
189. Yu M., et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006, 26:174-179.
190. Zhang G.X., et al. A paradoxical role of APCs in the induction of intravenous tolerance in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2005, 161:101-112.
191. Zhang R., et al. MCP-1 chemokine receptor CCR2 is decreased on circulating monocytes in sporadic amyotrophic lateral sclerosis (sALS). J. Neuroimmunol. 2006, 179:87-93.
192. Zhao W., et al. Extracellular mutant SOD1 induces microglial-mediated motoneuron injury. Glia 2010, 58:231-243.
193. Zhao W., et al. Regulatory T lymphocytes from ALS mice suppress microglia and effector T lymphocytes through different cytokine-mediated mechanisms. Neurobiol. Dis. 2012, 48:418-428.
194. Zhao W., et al. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J. NeuroImmune Pharmacol. 2013, 8:888-899.
195. Zhong Z., et al. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat. Neurosci. 2008, 11:420-422.
196. Zhou F., et al. Intravenous transfer of apoptotic cell-treated dendritic cells leads to immune tolerance by blocking Th17 cell activity. Immunobiology 2013, 218:1069-1076.
197. Zhu B., et al. Plasticity of Ly-6C(hi) myeloid cells in T cell regulation. J. Immunol. 2011, 187:2418-2432.